Retrospective analysis of a group of patients with advanced Non-Small-Cell lung cancer (NSCLC) treated with Gefitinib

被引：0
|
作者：
Bandera, M. [1 ]
Bascialla, L. [1 ]
Martinelli, B. [1 ]
Masera, G. L. Rodolfo [1 ]
Vallini, I. [1 ]
Zanlorenzi, L. [1 ]
Pinotti, G. [1 ]
机构：
[1] Osped Circolo & Fondazione Macchi, UO Oncol Med, Varese, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [21] Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
    Passaro, Antonio
    Alesini, Daniele
    Pochesci, Alessia
    Cortesi, Enrico
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 646 - 650
  • [22] Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
    Buti, Sebastiano
    Chiesa, Matteo Dalla
    Tomasello, Gianluca
    Negri, Federica
    Machiavelli, Andrea
    Bosio, Giancarlo
    Stifani, Italo
    Betti, Monia
    Buononato, Massimo
    Passalacqua, Rodolfo
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 21 - 21
  • [23] Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer
    Kaneda, H
    Tamura, K
    Kurata, T
    Uejima, H
    Nakagawa, K
    Fukuoka, M
    [J]. LUNG CANCER, 2004, 46 (02) : 247 - 254
  • [24] Effect of EGFR mutations on gefitinib in advanced previous treated non-small-cell lung cancer
    Guo, J.
    Zhou, C.
    Deng, Q.
    Ren, S.
    Zhang, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] The lifetime cost of gefitinib ("Iressa") in treating patients with non-small-cell lung cancer (NSCLC)
    Haiderali, A
    Chin, W
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 671 - 671
  • [26] Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib
    Ma, Fei
    Sun, Tong
    Shi, Yuankai
    Yu, Dianke
    Tan, Wen
    Yang, Ming
    Wu, Chen
    Chu, Datong
    Sun, Yan
    Xu, Binghe
    Lin, Dongxin
    [J]. LUNG CANCER, 2009, 66 (01) : 114 - 119
  • [27] Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
    Tiseo, M.
    Bartolotti, M.
    Gelsomino, F.
    Bordi, P.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 81 - 98
  • [28] Cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Pirker, Robert
    [J]. LUNG CANCER, 2012, 77 : S13 - S14
  • [29] Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
    C Gridelli
    P Maione
    V Castaldo
    A Rossi
    [J]. British Journal of Cancer, 2003, 89 : 1827 - 1829
  • [30] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Cappuzzo, F
    Magrini, E
    Ceresoli, GL
    Bartolini, S
    Rossi, E
    Ludovini, V
    Gregorc, V
    Ligorio, C
    Cancellieri, A
    Damiani, S
    Spreafico, A
    Paties, CT
    Lombardo, L
    Calandri, C
    Bellezza, G
    Tonato, M
    Crinò, L
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) : 1133 - 1141
12345